ARIA. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir boosted atazanavir plus tenofovir disoproxil fumarate and entricitabine in previously untreated women with HIV1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
Orrell C, Hagins DP, Belonosova E, Porteiro N, Walmsley S, Falcó V, Man CY, Aylott A, Buchanan AM, Wynne B, Vavro C, Aboud M, Smith KY; ARIA study team. Lancet HIV. 2017 Dec;4(12):e536-e546. doi: 10.1016/S2352-3018(17)30095-4.